Endometriosis: Gynecology 5 Course 1 Obstetrical and Gynecological Clinic MMA
Endometriosis: Gynecology 5 Course 1 Obstetrical and Gynecological Clinic MMA
Endometriosis: Gynecology 5 Course 1 Obstetrical and Gynecological Clinic MMA
Definition of Endometriosis
presence of endometrial tissue, composed of glands and stroma, at sites outside endometrial cavity most common sites
endometrial tissue responds cyclically to estrogen severity of pain unrelated to extent of disease
There may be more pain associated with active lesions in mild disease than with adhesions in severe disease swelling producing local inflammation
metaplasia of mesothelial cells into endometrial epithelium under some unidentified influence, such as repeated inflammation
Hematogenous spread
Epidemiology
found equally among all races more likely to occur and progress in women with
early menarche in those with menstrual flow exceeding seven days cycles of less than 27 days years of menstruation uninterrupted by pregnancy family history of endometriosis
Incidence
10-15 % of women of reproductive age 40-50 % of women undergoing surgery for evaluation of infertility average age at diagnosis is 28
Risk factors
Single/nulliparous Early menarche Non-oral contraception Shorter cycle/longer duration of flow Dysplastic naevus syndrome, melanoma
History
cervical displacement of 1 cm or more to the left or right of midline bimanual exam: tenderness and nodularity of the uterosacral ligaments and posterior cul-desac(Douglas space) are detected adnexal masses that vary in size, shape, and consistency and may be asymmetric, fixed, cystic, or indurated fixed retroversion of the uterus
Diagnostic Tests
CA-125 elevated (Tumour marker) FBC normal ESR normal Diagnostic laparoscopy
Differential Diagnoses
chronic PID recurrent acute salpingitis hemorrhagic corpus luteum benign or malignant ovarian neoplasm ectopic pregnancy adenomyosis
Treatment Plan
psychosocial intervention medications
Danazol (ovarian inhibitor) progesterones combined Oral Contraceptives gonadotropin-releasing hormone agonists (GnRH-a)
Lupron injection qmo x 6 mos Synarel nasal spray bid x 6 mos
GnRH analogs
Decreases secretion of gonadotropins Major concerns are
Cost Parenteral administration Potential for accelerated bone mineral loss Hot flushes & hypo-estrogen states
Treatment of pain
NSAIDS: all significantly better than placebo, studies vary which one is best Naproxen >mefanemic acid>aspirin Naproxen=ibuprofen Naproxen only drug with significant SEs